RxDoctor Payments Data

Teirza Bristow

Primary Care · Kellogg, IDNPI 1700363348

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 231 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 27.1% of the total. Among primary care clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,986in general payments, 2019–2025

Across 231 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$490
  • GSK$396
  • Pfizer$289
  • Novo Nordisk$274
  • Lilly USA, LLC$209
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,986100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,986 in reported general payments places this provider in the 90th percentile of 48 primary care providers in Idaho.

See all primary care providers in Idaho

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$62,541
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$56,513
EliquisApixaban26$35,895
JardianceEmpagliflozin30$31,920
Aimovig AutoinjectorErenumab-Aooe15$16,499
Tresiba Flextouch U-200Insulin Degludec25$16,395
Nurtec OdtRimegepant Sulfate14$16,388
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$10,757
Breo ElliptaFluticasone/Vilanterol19$8,977
VascepaIcosapent Ethyl27$8,860
MyrbetriqMirabegron13$5,732
TrintellixVortioxetine Hydrobromide12$5,441
Eletriptan HbrEletriptan Hydrobromide13$5,409
BelsomraSuvorexant12$5,180
Ventolin HfaAlbuterol Sulfate48$4,435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$396$65,48987 claims
Novo NordiskOzempic$274$62,54145 claims
PfizerEliquis, Nurtec Odt$289$52,28340 claims
Boehringer IngelheimJardiance$90$31,92030 claims
AstraZenecaBreztri Aerosphere$59$10,75717 claims
AbbVieSynthroid$1,081$1,24523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 48 primary care providers in Idaho.

Other primary care in Kellogg

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →